LEK-8842

LEK-8842, also known as N-methyl-N-(2-propynyl)lysergamide or as TRALA-01, is a serotonin receptor modulator of the lysergamide family related to the psychedelic drug LSD.^[1][2][3]

Other namesLEK8842; TRALA-01; N-Methyl-N-(2-propynyl)lysergamide; 9,10-Didehydro-N-methyl-N-(2-propynyl)-6-methylergoline-8β-carboxamide; "Compound 2a"

Drug classSerotonin receptor modulator; Serotonin 5-HT_2A receptor agonist

ATC code

• None

PubChem CID

• 164461

Quick facts Clinical data, Other names ...

LEK-8842

Clinical data
Other names	LEK8842; TRALA-01; N-Methyl-N-(2-propynyl)lysergamide; 9,10-Didehydro-N-methyl-N-(2-propynyl)-6-methylergoline-8β-carboxamide; "Compound 2a"
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code	None
Identifiers
IUPAC name (6aR,9R)-N,7-dimethyl-N-prop-2-ynyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChem CID	164461
ChemSpider	64883692
ChEMBL	ChEMBL5618531
Chemical and physical data
Formula	C20H21N3O
Molar mass	319.408 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)N(C)CC#C
InChI InChI=1S/C20H21N3O/c1-4-8-22(2)20(24)14-9-16-15-6-5-7-17-19(15)13(11-21-17)10-18(16)23(3)12-14/h1,5-7,9,11,14,18,21H,8,10,12H2,2-3H3/t14-,18-/m1/s1 Key:NTIBYWGZNANJNM-RDTXWAMCSA-N

Close

The drug is described as showing serotonin 5-HT₂ receptor partial agonistic activity and α-adrenergic receptor agonistic activity based on in-vitro tissue assays that included selective antagonist challenges.^[1][2] Subsequently, it was found to be a potent partial agonist of the serotonin 5-HT_2A and 5-HT_2B receptors and to show affinity for the serotonin 5-HT_2C receptor.^[3] LEK-8842 produces effects in animals including serotonin behavioral syndrome, hyperthermia, pressor effects, pupil dilation, and uterine contractions.^[2]

The chemical synthesis of LEK-8842 has been described.^[3] Several analogues of LEK-8842 have been described, for instance LEK-8804 (N-(2-propynyl)lysergamide) among others.^[2][4][5]

LEK-8842 was first described in the scientific literature by 1992.^[2] It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals.^[2] Subsequently, LEK-8842 was studied and patented by Matthias Liechti and Daniel Trachsel and colleagues in association with Mind Medicine (Definium Therapeutics) in 2023.^[3]